METHODS: We used a cryptorchid rat testes model of SSC disturbance. The model was generated using intra-abdominal injection of flutamide (7.5 mg/rat) into pregnant Sprague-Dawley rats. Normal testes, unilateral undescended testes (UDT), and contralateral descended testes (DT) were extirpated on postnatal day 9, when two types of SSCs (gonocytes and spermatogonia) co-existed and gonocytes began differentiation into spematogonia. A microarray examining DT and UDT focused on miR-135a, which exhibited lower expression in UDT. In situ hybridization (ISH) was used for the detection of the localization of miR-135a and quantitative polymerase chain reaction (qPCR) to determine the organ specificity of the gene. We then searched the miR-135a target genes using a computer program, followed by the luciferase assay to demonstrate the suppression effect of miR-135a in vitro.
INTRODUCTION AND OBJECTIVES:
Recently male late-onset hypogonadism syndrome (LOH syndrome) is focused on with various symptoms due to hypogonadism. Although the results of the differentiation instructions from human induced pluripotent stem cell (human iPS cells) to many various cells, there is no report that succeed in induced Leydig cell which secret androgens. In this time we succeeded in Induced Leydig cell secrete testosterone from human iPS cells.
METHODS: First, we transduced NR5A1 expressing system by doxycycline addition to human iPS cell. We examined various genetic expression and hormone producing ability and evaluate the differentiation instruction from this cell under a timing of the NR5A1 forced expression and various kinds of conditions. Human iPS cells-derived testosterone-producing Leydig cells were transplanted into castrated male rats and examined for improvement in serum testosterone levels.
RESULTS: Leydig cell marker (INSL3 variant2) and LH receptor (LHCGR) and Leydig cell-specific enzyme (17bHSD3)and expression of various enzyme (StAR,CYP11A,3bHSD2,CYP17A) necessary for testosterone production were confirmed in RT-PCR.INSL3 and LHCGR were confirmed in Immunohistochemical staining.Testosterone production was confirmed by the hormone measurement in supernatants. And we showed that transplantation of human iPS cells-derived testosterone-producing Leydig cells to castrated rats ameliorate serum testosterone levels.At the same time, expression of adrenal cortexspecific enzyme (CYP21A2,CYP11B1,CYP11B2) necessary for cortisol and aldosterone production were confirmed in RT-PCR. The cluster of Leydig cells include the adrenal cortex cells too.
CONCLUSIONS: We succeeded in Leydig cell instruction from human iPS cells. At the same time to adrenocortical cell is induced, and we will examine the specific differentiation instruction conditions to Leydig cell in future. Transplantation of human iPS cells-derived testosterone-producing Leydig cells to castrated rats ameliorate serum testosterone levels. METHODS: To demonstrate the feasibility of restoring functional volumetric tissues in the defect site, multiple, progressive delivery of cells was performed using ectopic cell transplantation in a subcutaneous site. Appropriate cell delivery parameters such as cell density, cell injection volume, and time interval between injections were tested. The efficiency of volumetric tissue formation was compared with single injection of the same number of cells that were used for multiple injections in ectopic and in situ volumetric muscle loss models. Histological and functional recovery was evaluated to determine the possibility for applications to treat critical-size muscle defects.
RESULTS: Multiple-cell injections with one-week interval between each injection resulted in an increased volume of the implants. Quantitatively, increased number of cell injections (up to 8 injections) correlated with an increased implant volume. Particularly, 6-8 cell injections demonstrated a statically significant difference when compared with 2-4 cell injections. The volumes of implants in all multiple, progressive cell injected groups showed a significant increase compared to the progressive gel only-injected groups (ANOVA, P<0.001). Histologically, an increase in the volume of reconstructed tissue formation was notable between 2 and 4 cell injections, but no significant size difference was observed beyond 4 cell injections. In each group, the newly formed tissue structures were skeletal muscle fibers as confirmed within the implant.
CONCLUSIONS: Progressive multiple cell injections yielded improved cell survival and formed volumetric muscle tissues in an ectopic muscle site. Results from this study suggest that this method can be used to repair volumetric tissue defects by overcoming diffusion limitations and facilitating adequate vascularization. 
PD33-12 IN VIVO EVALUATION OF FUNCTIONALIZED MUSCLE SCAFFOLDS FOR RECONSTRUCTION
Lindsey Shapiro, Young Min Ju, John Jackson, James Yoo, Anthony Atala, Sang Jin Lee*, Winston Salem, NC INTRODUCTION AND OBJECTIVES: It has been demonstrated that almost every tissue in the body contains some type of stem or progenitor cells. These cells are believed to be part of underlying regenerative machinery that is responsible for daily maintenance and repair of injured tissue. The presence of an underlying regenerative mechanism in the form of tissue-specific stem and progenitor cells e654 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 suggests that there may be a potential opportunity to bias the host response towards repair and replacement of tissue defects. This may be achieved by maneuvering host stem and progenitor cells using target specific scaffolds. In this study, we aimed to regenerate muscle functionality following volumetric muscle loss through the use of a targetspecific scaffolding system. The objectives of this study were to evaluate the functionalized decellularized tissue scaffolds on the host muscle cell migration and muscle function recovery in vivo. METHODS: Decellularized porcine scaffolds were implanted into a created defect site in the tibialis anterior muscle of rats. Three experimental groups were tested (along with two control groups); those with empty scaffolds, scaffolds seeded with muscle progenitor cells, and scaffolds injected with IGF-1 prior to implantation. To evaluate the effect of the scaffolds, a force transducer was utilized to measure isometric force produced by the tibialis anterior muscle at either 2 or 4 weeks post-implantation. To evaluate the cell infiltration of the scaffolds, the muscle and scaffold were removed and characterized by H&E and Masson 0 s Trichrome. RESULTS: Functional testing showed an increase in muscle functionality in all groups by 4 weeks relative to the defect only group. Scaffolds seeded with primary muscle cells recovered 53% of functionality by week 4, a 21% increase over the defect only group. The retrieved implants showed progressive cell infiltration of the scaffolds over time. The IGF-1 and seeded progenitor cell scaffolds yielded the greatest cell count. Fiber-like orientation of infiltrated cells within the scaffold could be seen as early as week 2. CONCLUSIONS: Our data suggest an ability of host stem cells to recruit into the scaffolds with the capability of differentiating to muscle cells, which resulted in accelerating muscle regeneration in situ. This study hopes to provide a platform for the development of tissue engineering and regenerative medicine in regards to volumetric muscle loss. INTRODUCTION AND OBJECTIVES: Prostate retreatment for locally recurrent prostate cancer (PC) after definitive radiation therapy is infrequently considered. Most men who develop biochemical failure are reflexively started on hormone therapy (ADT). However, as the toxicity of ADT becomes increasingly evident, non-curative therapy that results in prolonged ADT-free survival may be beneficial. We report our experience with salvage prostate cryoablation and its clinical impact and benefit.
METHODS: Patients were identified from a prospective database of men undergoing salvage cryoablation after definitive prostate radiation by EBRT, brachytherapy, or both. Inclusion required having non-metastatic, biopsy-confirmed, locally recurrent PC with complete PSA information. Pre-and post-salvage PSA characteristics were assessed. A one-sided paired samples T-test (significance p <0.05) was used to evaluate the effect of prostate cryoablation on serum PSA. RESULTS: Of 56 identified men, 52 cases met criteria for analysis. Median time between radiation and salvage was 88mo ). Median follow-up was 12mo (IQR 4-24mo). The pre-and post-salvage median PSAs were, respectively, 5.49 (IQR 5.68) and 0.14 (IQR 1.16), which were significantly different (mean difference 4.93, 95% CI 3.83-6.03, p <0.001). The median PSA decline following treatment was 96.1% (IQR 33.8%). 29 (56%) men achieved an undetectable nadir PSA. At last follow-up, 41 (79%) men have not progressed to ADT; 11 (21.2%) men eventually received ADT at a median time to initiation of 9mo . Figure 1 demonstrates the observed pattern for salvage therapy.
CONCLUSIONS: Salvage prostate therapy for locally recurrent PC is beneficial for men able to defer ADT initiation. 56% of men demonstrated a complete PSA nadir following salvage cryoablation, suggestive for possible curative outcomes. Even for men with a nonzero PSA after salvage, the majority did not require ADT; and 41 (80%) men remain free from treatment within the follow-up period. Salvage prostate cryoablation is an effective secondary treatment that results in prolonged ADT-free survival in carefully selected men. Further follow-up will help define the extent of response and duration of ADT-free survival following salvage therapy. Salvage radical prostatectomy (sRP) and salvage cryotherapy (sCryo) are both treatment strategies that have been associated with durable recurrence free survival in such patients; however, there is a paucity of long-term comparative outcomes following these treatments. We compared long-term outcomes using mature data from two large single-center cohorts.
METHODS: Men undergoing salvage treatment for localized radiorecurrent prostate cancer at two large academic centers between 1988 and 2004 were identified. One center performed sRP, and the other performed sCryo. Prospectively recorded data on preoperative characteristics, oncological outcomes, and perioperative morbidity were analyzed. Urinary continence and erectile function were assessed at 1 year. Primary outcomes were overall survival (OS) and disease-specific survival (DSS). Secondary outcomes were freedom from castrateresistant prostate cancer (CRPC) and freedom from androgen deprivation therapy (ADT). Data were compared using the Kaplan-Meier method.
RESULTS: 251 men underwent sRP and 187 were treated with sCryo. Men undergoing sCryo were older than those undergoing sRP (median 69 vs 65.8 yrs, p<0.001). Pre-salvage therapy PSA values and
